CVS Health (CVS) Caremark Delivers Expanded Coverage Options for GLP-1 Weight Management Medications
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
May 28, 2026 6:45 AM EDTExpanded GLP-1 options for members create a path to sustainable coverage of these important medications
WOONSOCKET, R.I., May 28, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members including the reintroduction of Zepbound® (tirzepatide) as a covered medication. These changes build on Caremark's industry leading efforts as a pharmacy benefits manager to explore all potential avenues that... More
